Languages

Currency

Semaglutide (GLP-1) 5mg

Semaglutide (GLP-1) 5mg

GLP-1 receptor agonist Semaglutide Research Topics:

  1. Glycemic Control:

    Semaglutide significantly lowers blood glucose levels in individuals with type 2 diabetes by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying (PMID: 32910488, PMID: 32910487).

  2. Weight Loss:

    It promotes substantial weight loss by reducing appetite and increasing feelings of fullness, which helps in the management of obesity (PMID: 32910488, PMID: 32910487).

  3. Cardiovascular Benefits:

    Semaglutide reduces the risk of major adverse cardiovascular events, including heart attack and stroke, making it beneficial for patients with type 2 diabetes at high cardiovascular risk (PMID: 32910488, PMID: 33068776).

  4. Anti-Inflammatory Effects:

    It decreases postprandial inflammation markers such as IL-6, which contributes to better overall metabolic health (PMID: 32910488).

Related Research

The differences in weight loss percentages for GLP-1 (Semaglutide), GLP-1/GIP (Tirzepatide), and GLP-1/GIP/GCGR (Retatrutide) are as follows:

  1. Semaglutide (GLP-1):

    In clinical trials, Semaglutide resulted in a weight loss of approximately 12% over a period of 68 weeks (PMID: 32910488).

  2. Tirzepatide (GLP-1/GIP):

    Tirzepatide demonstrated a weight loss ranging from 15% to 21% in different studies over a period of 72 weeks (PMID: 32910487).

  3. Retatrutide (GLP-1/GIP/GCGR):

    In a phase 2 trial, Retatrutide showed a placebo-subtracted weight loss ranging from 6.6% to 22.1% over 48 weeks (PMID: 37366315).

 

Peer-Reviewed Studies 

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). New England Journal of Medicine.

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Vilsbøll, T. (2016). N Engl J Med375, 1834-1844.

Structure

Sequence: HXEGTFTSDVSSYLEGQAAK­
OH.steric diacid-EFIAWLVRGRG
Molecular Formula: C187H291N45O59 Molecular Weight: 4113.64 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535

$136.00

Description

GLP-1 receptor agonist Semaglutide Research Topics:

  1. Glycemic Control:

    Semaglutide significantly lowers blood glucose levels in individuals with type 2 diabetes by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying (PMID: 32910488, PMID: 32910487).
  2. Weight Loss:

    It promotes substantial weight loss by reducing appetite and increasing feelings of fullness, which helps in the management of obesity (PMID: 32910488, PMID: 32910487).
  3. Cardiovascular Benefits:

    Semaglutide reduces the risk of major adverse cardiovascular events, including heart attack and stroke, making it beneficial for patients with type 2 diabetes at high cardiovascular risk (PMID: 32910488, PMID: 33068776).
  4. Anti-Inflammatory Effects:

    It decreases postprandial inflammation markers such as IL-6, which contributes to better overall metabolic health (PMID: 32910488).

Related Research

The differences in weight loss percentages for GLP-1 (Semaglutide), GLP-1/GIP (Tirzepatide), and GLP-1/GIP/GCGR (Retatrutide) are as follows:

  1. Semaglutide (GLP-1):

    In clinical trials, Semaglutide resulted in a weight loss of approximately 12% over a period of 68 weeks (PMID: 32910488).
  2. Tirzepatide (GLP-1/GIP):

    Tirzepatide demonstrated a weight loss ranging from 15% to 21% in different studies over a period of 72 weeks (PMID: 32910487).
  3. Retatrutide (GLP-1/GIP/GCGR):

    In a phase 2 trial, Retatrutide showed a placebo-subtracted weight loss ranging from 6.6% to 22.1% over 48 weeks (PMID: 37366315).

 

Peer-Reviewed Studies 

Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Kushner, R. F. (2021). New England Journal of Medicine.

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Vilsbøll, T. (2016). N Engl J Med375, 1834-1844.

Structure

Sequence: HXEGTFTSDVSSYLEGQAAK­
OH.steric diacid-EFIAWLVRGRG
Molecular Formula: C187H291N45O59 Molecular Weight: 4113.64 g/mol
PubChem CID: 56843331
CAS Number: 910463-68-2
Synonyms: Semaglutide, Oxempic, Rybelsus, NN9535

Reviews

There are no reviews yet.

Be the first to review “Semaglutide (GLP-1) 5mg”

Your email address will not be published. Required fields are marked *

x

Daily Promotion

Sign up newsletter